Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease

Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease

Background: Dysphagia is a potentially fatal symptom of Parkinson’s disease (PD) and is characterized by frequent silent aspiration, a known risk factor for aspiration pneumonia. A previous study has reported that the dopamine agonist rotigotine (levodopa equivalent dose of 60 mg/day) delivered via...

Full description

Saved in:
Bibliographic Details
Main Authors: Makito Hirano, Makoto Samukawa, Chiharu Isono, Rino Inada, Yuta Fukumoto, Keisuke Yoshikawa, Hitoshi Namura, Hanami Sakata, Takahiro Hisatomi, Toru Michiura, Hiroto Nakamura, Akira Morita, Genki Hoshino, Kensuke Yamana, Atsushi Terayama, Yuji Higashimoto, Yoshiyuki Mitsui, Yoshitaka Nagai
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Clinical Parkinsonism & Related Disorders
Subjects:
Dysphagia
Parkinson’s disease
DOSS
Deglutition
CSCI of foslevodopa/foscarbidopa
Online Access:http://www.sciencedirect.com/science/article/pii/S2590112525000829
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590112525000829

Similar Items